{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:46:29Z","timestamp":1740134789787,"version":"3.37.3"},"reference-count":10,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,3,24]]},"DOI":"10.1182\/blood-2016-02-694877","type":"journal-article","created":{"date-parts":[[2016,3,24]],"date-time":"2016-03-24T12:34:31Z","timestamp":1458822871000},"page":"1523-1524","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Ibrutinib: a force with a dark side?"],"prefix":"10.1182","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1428-8765","authenticated-orcid":false,"given":"Mitchell R.","family":"Smith","sequence":"first","affiliation":[{"name":"CLEVELAND CLINIC"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"12","key":"2019111902370529100_B1","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma.","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"issue":"13","key":"2019111902370529100_B2","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","article-title":"Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.","volume":"125","author":"Jain","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2019111902370529100_B3","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"10020","key":"2019111902370529100_B4","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"issue":"24","key":"2019111902370529100_B5","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib.","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111902370529100_B6","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.","volume":"4","author":"Chiron","year":"2014","journal-title":"Cancer Discov"},{"issue":"2","key":"2019111902370529100_B7","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1182\/blood-2014-07-585364","article-title":"Proteasome inhibitor carfilzomib complements ibrutinib\u2019s action in chronic lymphocytic leukemia.","volume":"125","author":"Lamothe","year":"2015","journal-title":"Blood"},{"issue":"20","key":"2019111902370529100_B8","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1182\/blood-2011-10-388298","article-title":"Selective CDK4\/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.","volume":"119","author":"Leonard","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2019111902370529100_B9","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/bjh.13149","article-title":"Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways.","volume":"168","author":"Zhao","year":"2015","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111902370529100_B10","doi-asserted-by":"crossref","first-page":"e0130590","DOI":"10.1371\/journal.pone.0130590","article-title":"Progression and transformation of clonally heterogeneous B-cell lymphoma.","volume":"10","author":"Weiss","year":"2015","journal-title":"PLoS One"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/127\/12\/1523\/1391974\/1523.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/127\/12\/1523\/1391974\/1523.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T02:39:01Z","timestamp":1574131141000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/127\/12\/1523\/35023\/Ibrutinib-a-force-with-a-dark-side"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,24]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,3,24]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-02-694877","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"type":"print","value":"0006-4971"},{"type":"electronic","value":"1528-0020"}],"subject":[],"published":{"date-parts":[[2016,3,24]]}}}